Asia Pacific: In Asia Pacific, countries like China, Japan, and South Korea are witnessing a growing prevalence of retinoblastoma, leading to an increasing demand for treatment options. The market is also benefiting from government initiatives to improve healthcare services and raise awareness about early diagnosis and treatment.
Europe: The Retinoblastoma Treatment Market in Europe is experiencing significant growth, particularly in the United Kingdom, Germany, and France. The availability of advanced treatment facilities and a rise in healthcare expenditure are driving the market growth in these countries.